Understanding the Financial Health of Viking Therapeutics Inc. (VKTX)

    Publicly-traded company Viking Therapeutics Inc. (NASDAQ:VKTX) had a closing price of $7.82 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $24.30, this means that the stock is underpriced by 67.82%. In the past 52 weeks the company’s stock price has moved within the range of $6.15 to $14.77.

    This particular stock’s 5-day moving average is 6.82, its 20-day moving average is 6.62 and its 100-day moving average is 7.30. Viking Therapeutics Inc. (VKTX) currently has 69.52M shares outstanding, which means that its market capitalization is $543.65M.

    The Details: Viking Therapeutics Inc. (VKTX) Financial Health

    Return on Assets is a number, expressed as a percentage that tells us how well a publicly-traded company is using its current assets to generate revenue. The higher the percentage, the better a company is using its assets to turn a profit. At the moment, Viking Therapeutics Inc. Return on Assets is -8.10%.

    What Does Wall Street Say about Company?

    When choosing stocks, many investors search for what Wall Street professionals think about the company first – like what the average rating is. At the moment, the average analyst rating for VKTX is Buy. Out of 11 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 11 rated it a Buy.

    Understanding Profitability at Viking Therapeutics Inc. (VKTX)

    Taking a look at a public company’s Earnings per Share (EPS) is a good way of evaluating its profitability. In the most recent financial results released by Viking Therapeutics Inc., for the quarter ending on 09/2019, the company posted EPS of -0.13. The average estimate of Wall Street analysts had projected -0.11.

    Wall Street analysts, on average, are forecasting the company’s EPS to be -0.13, compared to -0.11 reported in the same quarter last year.